**Trader consensus heavily favors no new COVID variant of concern before 2027, with "No" at 90.5%.** This reflects the stable global picture through mid-2026, where SARS-CoV-2 continues to evolve within established Omicron-descendant lineages without triggering the criteria for a new Variant of Concern (VOC). WHO maintains a moderate public health risk assessment as of late July 2026, noting ongoing circulation but reduced overall impact due to population immunity and clinical management. Dominant or rising strains such as XFG, NB.1.8.1, PQ.16.1.1, and BA.3.2 remain classified only as Variants Under Monitoring (VUMs), with no recent elevation to VOI or VOC status. Vaccine advisory panels are recommending updates for the 2026–2027 season targeting these JN.1-lineage variants, underscoring incremental antigenic drift rather than a disruptive shift. With roughly four months remaining in 2026 and no evidence of rapid emergence of a lineage with markedly higher transmissibility, severity, or immune escape in recent surveillance data, traders see limited scope for a qualifying new VOC before the year ends. Resolution would hinge on WHO formally designating one based on its standardized criteria for potential public health impact.